<DOC>
	<DOCNO>NCT01435265</DOCNO>
	<brief_summary>This phase IV randomize , prospective open label study asses efficacy extend nurse eduction program improve adherence prescribe treatment regimen treatment moderate severe psoriasis vulgaris .</brief_summary>
	<brief_title>Nurse Education Subjects With Psoriasis Undergoing Treatment With Adalimumab</brief_title>
	<detailed_description>This phase IV randomize , prospective open label study asses efficacy extend nurse eduction program improve adherence prescribe treatment regimen treatment moderate severe psoriasis vulgaris . Twenty subject , male female , age 18 old good health moderate severe chronic plaque type psoriasis adalimumab indicate accord adalimumab prescribe information . All subject must negative TB skin test accord prescribe guideline . Subjects must start adalimumab first time , prescribed physician . This open label trial . All subject receive adalimumab prescribe physician . Half group randomize receive additional nurse education program , half receive normal education material provide physician .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects must male female , 18 year age great , good health moderate severe plaque psoriasis adalimumab indicate accord adalimumab prescribe information . All subject must negative TB skin test accord prescribe guideline . Subjects must start adalimumab first time , prescribed dermatologist . Must give write informed consent . Subject must adult male nonpregnant , nonlactating female . Female subject childbearing potential must state use measure avoid conception active mean include , abstinence , oral contraceptive , intrauterine device , DepoProvera , Norplant , tubal ligation , vasectomy partner monogamous relationship . Subjects may concomitant systemic medication psoriasis methotrexate , acitretin , etretinate , cyclosporine , prednisone ot biological agent receive phototherapy baseline visit , specific washout treatment require . There washout topical medication . Stable dose topical medication may use throughout duration study . Subjects skin condition disease may require concurrent therapy may confound evaluation . Subjects history hypersensitivity adalimumab history hypersensitivity formulation component exclude study . Female subject postmenopausal least one year , surgically sterile willing practice effective contraception study . Nursing mother , pregnant woman woman plan become pregnant study exclude . Current enrollment research study involve investigational drug . Serious local infection systemic infection within three month prior first dose investigational drug . Treatment another investigational drug within one month prior study drug administration . Concurrent treatment systemic retinoids , systemic steroid , methotrexate , cyclosporine , azathioprine , thioguanine , etanercept , efalizumab , infliximab mofetil systemic immunosuppressant agent . Any active history HIV , Hepatitis tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Phase IV</keyword>
	<keyword>Nurse Education</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Humira</keyword>
</DOC>